The 'Outperform' rating maintained by Raymond James indicates a positive outlook for bluebird bio. The increase in the price target from $10 to $13 suggests that the analyst believes the stock has potential for growth in the short term. This could lead to an increase in investor confidence and potentially a rise in the stock price.